Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have received a consensus rating of "Moderate Buy" from the fifteen analysts that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, ten have given a buy…
